Merck Wins Defense Verdict In 1st Fosamax Femur Case To Go To Verdict

Merck Wins Defense Verdict In 1st Fosamax Femur Case To Go To Verdict

TRENTON, N.J. - A New Jersey federal jury on April 29 quickly found that Fosamax did not cause a plaintiff's femur fracture, the first verdict in a case in which a plaintiff claims that the osteoporosis drug weakened her thigh bone (In Re: Fosamax [Alendronate Sodium] Products Liability Litigation, MDL Docket No. 08-md-00008, Bernadette Glynn, et al. v. Merck Sharp & Dohme Corporation, No. 11-5304, D. N.J.).

Find full version on lexis Advance®
Access this news story on lexis.com®